Clinical pharmacodynamics of antifungals

被引：20

作者：

Andes, D ^{[1
]}

机构：

[1] Univ Wisconsin, Dept Med, Infect Dis Sect, Madison, WI 53792 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2003年 / 17卷 / 03期

关键词：

D O I：

10.1016/S0891-5520(03)00063-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 [免疫学];

摘要：

Antimicrobial pharmacodynamics describes the relationship between drug concentration over time, or pharmacokinetics, and treatment outcome. Pharmacodynamic studies provide information useful for dosing interval and dose level selection and for the development of in vitro susceptibility guidelines. Pharmacodynamic observations from animal model studies have proved useful for outcome predictions in treatment of human infections. The strength of these predictions has been shown most clearly for antibacterial drugs. Recent studies suggest that similar analyses may be useful for the clinical development of antifungal drugs.

引用

页码：635 / +

页数：17

共 56 条

[1]

Animal model pharmacokinetics and pharmacodynamics: a critical review [J].

Andes, D ;

Craig, WA .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268

[2]

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Lowther, J ;

Bryskier, A ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1187-1192

[3]

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].

Andes, D ;

van Ogtrop, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120

[4]

In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model [J].

Andes, D ;

van Ogtrop, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :938-942

[5]

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].

Andes, D ;

Craig, WA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379

[6]

In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1193-1199

[7]

In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis [J].

Andes, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1179-1186

[8]

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model [J].

Andes, D ;

Stamsted, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :922-926

[9]

FLUCONAZOLE-RESISTANT CANDIDOSIS IN AN HIV COHORT [J].

BAILY, GG ;

PERRY, FM ;

DENNING, DW ;

MANDAL, BK .

AIDS, 1994, 8 (06) :787-792

[10]

DNA SUBTYPES AND FLUCONAZOLE SUSCEPTIBILITIES OF CANDIDA-ALBICANS ISOLATES FROM THE ORAL CAVITIES OF PATIENTS WITH AIDS [J].

BARCHIESI, F ;

HOLLIS, RJ ;

MCGOUGH, DA ;

SCALISE, G ;

RINALDI, MG ;

PFALLER, MA .

CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :634-640

← 1 2 3 4 5 6 →